Study of Immunotherapy Drug Combination Treatment for Stage 4 Melanoma Patients Found A 52 Percent Five Year Survival Rate

You are viewing an old revision of this post, from October 20, 2019 @ 16:54:16. See below for differences between this version and the current revision.

A study of patients receiving a combination of two immunotherapy drugs approved for treating melanoma found such patients had a 52 percent five-year survival rate.

At a minimum follow-up of 60 months, the median overall survival was more than 60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.52; hazard ratio for death with nivolumab vs. ipilimumab, 0.63). Overall survival at 5 years was 52% in the nivolumab-plus-ipilimumab group and 44% in the nivolumab group, as compared with 26% in the ipilimumab group. No sustained deterioration of health-related quality of life was observed during or after treatment with nivolumab plus ipilimumab or with nivolumab alone. No new late toxic effects were noted.

Post Revisions:

Changes:

October 20, 2019 @ 16:54:16Current Revision
Content
Unchanged: <!-- wp:paragraph --> Unchanged: <!-- wp:paragraph -->
Unchanged: <p><a href="https:/ /www.nejm.org/ doi/full/10.1056/ NEJMoa1910836" class="ek-link">A study of patients</a> receiving a combination of two immunotherapy drugs approved for treating melanoma found such patients had a 52 percent five-year survival rate.</p> Unchanged: <p><a href="https:/ /www.nejm.org/ doi/full/10.1056/ NEJMoa1910836" class="ek-link">A study of patients</a> receiving a combination of two immunotherapy drugs approved for treating melanoma found such patients had a 52 percent five-year survival rate.</p>
Unchanged: <!-- /wp:paragraph --> Unchanged: <!-- /wp:paragraph -->
Unchanged: <!-- wp:quote --> Unchanged: <!-- wp:quote -->
Unchanged: <blockquote class="wp-block- quote"><p>At a minimum follow-up of 60 months, the median overall survival was more than 60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.52; hazard ratio for death with nivolumab vs. ipilimumab, 0.63). Overall survival at 5 years was 52% in the nivolumab-plus-ipilimumab group and 44% in the nivolumab group, as compared with 26% in the ipilimumab group. No sustained deterioration of health-related quality of life was observed during or after treatment with nivolumab plus ipilimumab or with nivolumab alone. No new late toxic effects were noted.</p></blockquote> Unchanged: <blockquote class="wp-block- quote"><p>At a minimum follow-up of 60 months, the median overall survival was more than 60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.52; hazard ratio for death with nivolumab vs. ipilimumab, 0.63). Overall survival at 5 years was 52% in the nivolumab-plus-ipilimumab group and 44% in the nivolumab group, as compared with 26% in the ipilimumab group. No sustained deterioration of health-related quality of life was observed during or after treatment with nivolumab plus ipilimumab or with nivolumab alone. No new late toxic effects were noted.</p></blockquote>
Unchanged: <!-- /wp:quote --> Unchanged: <!-- /wp:quote -->
  Added: <!-- wp:paragraph -->
  Added: <p>Typically, <a href="https:/ /www.healthline.com/health/ melanoma-prognosis- and-survival- rates#stage3" class="ek-link">the five year survival rate</a> for stage 4 melanoma has been in the 15-20 percent range.</p>
  Added: <!-- /wp:paragraph -->

Note: Spaces may be added to comparison text to allow better line wrapping.

Leave a Reply